Supply of Scopolamine Transdermal Systems

The contract solicits the supply of FDA-regulated scopolamine transdermal patch systems designed to prevent motion sickness, requiring full compliance with federal pharmaceutical standards for manufacturing, packaging, and labeling. All products must be packaged and labeled in accordance with current FDA guidelines, including proper identification, dosage instructions, and safety warnings, while also adhering to hazardous materials transportation regulations for the shipment of controlled pharmaceutical substances. The contract mandates complete documentation to support regulatory compliance, including material safety data sheets, shipping declarations, and chain-of-custody records required for hazardous pharmaceutical shipments. The procurement is issued under the Department of Defense’s Medical Supply Chain Pharma FSA, with performance required at Fort Bragg, North Carolina, 28310. This is a subcontract opportunity with no set-aside designation, open to qualified suppliers capable of delivering large-scale, consistent, and fully compliant quantities of the transdermal systems. Submissions must be received by July 29, 2026, and the National Industry Classification System code 325412 specifies the manufacturing of pharmaceutical preparations. All vendors must demonstrate proven capability in meeting stringent pharmaceutical quality controls and handling requirements specific to hazardous drug logistics within government supply chains.